Global Addiction Treatment Market to Surpass US$ 12,210.0 Million by 2028, Says Coherent Market Insights

SEATTLE, Jan. 28, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global addiction treatment market is estimated to be valued at US$ 8,297.0 million in 2021 and is expected to exhibit a CAGR of 5.3% over the forecast period (2021-2028).

Key Trends and Analysis of the Global Addiction Treatment Market:

Key trends in the market include the rising prevalence of addicted population, increasing product approvals and launches, initiatives by various organizations towards de-addiction, and increasing collaborations, partnerships, mergers and acquisitions among key players. These key trends are expected to aid in the growth of the addiction treatment market.

For instance, in May 2018, US WorldMeds LLC a Kentucky-based specialty pharmaceutical company received the U.S. Food and Drug Administration approval for its novel drug lofexidine hydrochloride (Lucemyra) for mitigation of opioid withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults.

Moreover, various government and private organizations are taking initiatives to spread awareness about nicotine de-addiction, which supports addicted person to quit smoking with the help of smoking cessation products. For instance, in 2017, the Public Health England launched US$ 1.3 million smoking cessation campaign to increase awareness to quit smoking.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4853 

Furthermore, key players operating in the global addiction treatment market are focusing on adoption of inorganic growth strategies such as acquisitions, mergers, partnerships, and collaborations, in order to strengthen their market presence in the global market. For instance, in August 2018, Elite Laboratories Inc. a specialty pharmaceutical company partnered with Glenmark Pharmaceuticals Ltd. a leading integrated research-based, global pharmaceutical company for distribution of its recently U.S. FDA approved methadone hydrochloride 5 mg and 10 mg tablets. As per the partnership Glenmark Pharmaceuticals, Inc., will sell and distribute methadone in the U.S. for Elite and Elite will receive manufacturing license for methadone.

Additionally, in March 2018, GlaxoSmithKline plc.(GSK) entered into an agreement to buyout Novartis AG a Switzerland based global healthcare company stake in the Consumer Healthcare joint venture. According to this agreement, Novartis AG divested its 36.5% stake in a consumer healthcare Joint Venture for total deal value of US$ 13 billion. This joint venture allows GSK to add Novartis' Nicotinell nicotine patch product into its portfolio. This product relieves and prevent cravings and withdrawl symptoms of nicotine. These factors are expected to boost growth of the addiction treatment market over the forecast period.

Key Market Takeaways:

The global addiction treatment market is expected to exhibit a CAGR of 5.3% over the forecast period, owing to increase in number of product approvals. For instance, in 2017, Akorn, Inc. and American generic pharmaceuticals manufacturer received the U.S. Food and Drug Administration (FDA) approval for generic versions of Methadone Hydrochloride Injection USP, 200 mg/20 mL (10 mg/mL) multi-dose vial. It is use treatment of opioid dependence. This generic drug is approved for temporary treatment of patients with opioid dependence, who are unable to take oral medication.

Among drug type, nicotine replacement therapies segment accounted for the largest market share in forecast period, owing to rising product launches. In 2018, Epic Pharma, LLC a generic pharmaceutical company launched Methadone Hydrochloride Tablets, USP in 5mg and 10mg strengths, the generic equivalent of Dolophine. Methadone Hydrochloride Tablets, USP are indicated for the treatment of opioid addiction as well as for management of pain indication.

Key players operating in the global addiction treatment market include Alkremes Plc., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, Titan Pharmaceuticals, Inc., Pfizer, Inc., GlaxoSmithKline plc. Johnson & Johnson, Perrigo Company plc., Cipla Limited, Hikma Pharmaceuticals Plc., Dr. Reddy's Laboratories Limited, Indivior Inc., and Mylan N.V.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/4853   

Detailed Market Segmentation:

Global Addiction Treatment Market, By Drug Type:

• Opioid Addiction
• Methadone
• Buprenorphine
• Naltrexone
• Alcohol Addiction
• Acamprosate
• Disulfiram
• Naltrexone
• Others
• Nicotine Replacement Therapies
• Nicotine Gums
• Nicotine Patches
• Nicotine Lozenges
• Nicotine Spray
• Nicotine Inhaler
• Nicotine Sublingual Tablets
• Non-Nicotine Medication
• Varenicline
• Bupropion (Zyban)

Global Addiction Treatment Market, By Region:

• North America
• By Country:
• U.S.
• Canada
• Europe
• By Country:
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country:
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East & Africa
• By Country:
• GCC Countries
• Israel
• South Africa
• Rest of Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/4853

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com 
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg